Oxypertine: Difference between revisions
Appearance
Content deleted Content added
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per [[Wikipedia:WikiProject Chemicals/Chembox vali |
m LTA |
||
(47 intermediate revisions by 25 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Antipsychotic medication}} |
|||
{{drugbox |
|||
{{Drugbox |
|||
| Verifiedfields = changed |
|||
| Watchedfields = changed |
|||
⚫ | |||
⚫ | |||
⚫ | |||
| width = 225 |
|||
<!--Clinical data--> |
|||
| tradename = |
|||
| Drugs.com = {{drugs.com|international|oxypertine}} |
|||
⚫ | |||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|||
| legal_BR = C1 |
|||
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-04-04}}</ref> |
|||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|||
| legal_DE = <!-- Anlage I, II, III or Unscheduled --> |
|||
| legal_NZ = <!-- Class A, B, C --> |
|||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|||
| legal_EU = |
|||
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> |
|||
⚫ | |||
⚫ | |||
<!--Pharmacokinetic data--> |
|||
⚫ | |||
| metabolism = |
|||
⚫ | |||
⚫ | |||
<!--Identifiers--> |
|||
| CAS_number_Ref = {{cascite|correct|??}} |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = 5JGL4G25R7 |
| UNII = 5JGL4G25R7 |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| KEGG_Ref = {{keggcite|correct|kegg}} |
| KEGG_Ref = {{keggcite|correct|kegg}} |
||
| KEGG = D01219 |
| KEGG = D01219 |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|||
| C = 23 | H = 29 | N = 3 | O = 2 |
|||
| ChemSpiderID = 4479 |
|||
| molecular_weight = 379.49 g/mol |
|||
⚫ | |||
<!--Chemical data--> |
|||
⚫ | |||
| |
| C=23 | H=29 | N=3 | O=2 |
||
⚫ | |||
⚫ | |||
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
|||
⚫ | |||
| StdInChI = 1S/C23H29N3O2/c1-17-19(20-15-22(27-2)23(28-3)16-21(20)24-17)9-10-25-11-13-26(14-12-25)18-7-5-4-6-8-18/h4-8,15-16,24H,9-14H2,1-3H3 |
|||
⚫ | |||
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
|||
⚫ | |||
| StdInChIKey = XCWPUUGSGHNIDZ-UHFFFAOYSA-N |
|||
⚫ | |||
}} |
}} |
||
'''Oxypertine''' ('''Equipertine''', '''Forit''', '''Integrin''', '''Lanturil''', '''Lotawin''', '''Opertil''') is an [[antipsychotic]] used in the treatment of [[schizophrenia]].<ref name="isbn0-412-54090-8">{{cite book |
'''Oxypertine''' ('''Equipertine''', '''Forit''', '''Integrin''', '''Lanturil''', '''Lotawin''', '''Opertil''') is an [[antipsychotic]] used in the treatment of [[schizophrenia]].<ref name="isbn0-412-54090-8">{{cite book | title = Dictionary of organic compounds | publisher = Chapman & Hall | location = London | year = 1996 | isbn = 0-412-54090-8 | url = https://books.google.com/books?id=5S_uhYzKWisC&q=oxypertine%20forit&pg=PA5038 | vauthors = Hall C, Rhodes PH }}</ref> It was also evaluated for the treatment of [[anxiety]] at a dosage of 20 mg per day.<ref name="pmid12484">{{cite journal | vauthors = Somohano MD, Broissin MC, Sobrino ZA | title = [Clinical evaluation of oxypertine in anxiety conditions] | language = es | journal = Neurologia, Neurocirugia, Psiquiatria | volume = 17 | issue = 3 | pages = 171–180 | date = 1976 | pmid = 12484 | doi = }}</ref> Chemically, it is an [[indole]] and [[phenylpiperazine]] [[chemical derivative|derivative]].<ref name="pmid4972600">{{cite journal | vauthors = Breulet M, Labar P, Delree C, Collard J, Bobon J | title = [Oxypertine, peperazine derivative of tryptophan with neuroleptic and dynamogenic properties] | language = fr | journal = Acta Neurologica et Psychiatrica Belgica | volume = 68 | issue = 2 | pages = 116–127 | date = February 1968 | pmid = 4972600 }}</ref> Like [[reserpine]] and [[tetrabenazine]], oxypertine depletes [[catecholamine]]s, though not [[serotonin]], possibly underlying its neuroleptic efficacy.<ref name="pmid5362847">{{cite journal | vauthors = Bak IJ, Hassler R, Kim JS | title = Differential monoamine depletion by oxypertine in nerve terminals. Granulated synaptic vesicles in relation to depletion of norepinephrine, dopamine and serotonin | journal = Zeitschrift für Zellforschung und Mikroskopische Anatomie | volume = 101 | issue = 3 | pages = 448–462 | year = 1969 | pmid = 5362847 | doi = 10.1007/BF00335580 | s2cid = 32583722 }}</ref> Its structure is similar to [[solypertine]] and [[milipertine]]. |
||
== See also == |
== See also == |
||
* [[Monoamine-depleting agent]] |
|||
* [[Antipsychotic]] |
|||
== References == |
== References == |
||
{{Reflist}} |
{{Reflist}} |
||
{{Antipsychotics}} |
{{Antipsychotics}} |
||
{{Adrenergics}} |
|||
{{Dopaminergics}} |
|||
{{Piperazines}} |
|||
{{Tryptamines}} |
{{Tryptamines}} |
||
[[Category: |
[[Category:Antipsychotics]] |
||
[[Category: |
[[Category:Catechol ethers]] |
||
[[Category: |
[[Category:Indole ethers at the benzene ring]] |
||
[[Category:Monoamine-depleting agents]] |
|||
[[Category:Phenylpiperazines]] |
|||
[[Category:Tryptamines]] |
|||
{{ |
{{Nervous-system-drug-stub}} |